GEN Exclusives

More »

GEN News Highlights

More »
Jun 7, 2011

Aros to Offer Data in CLC Bio Format to High-Throughput Sequencing Customers

  • Aros Applied Biotechnology will provide its high-throughput sequencing customers with the option to receive their data in the format of bioinformatics solution provider CLC bio. The arrangement between Aros and CLIC includes a time-limited license for the CLC Genomics Workbench desktop application for use in assembly and downstream sequence analyses.

    Aros' Total Genomic Solutions suite consists of GLP and GCP compliant services that range from extraction, sample banking, analysis (next-generation sequencing, microarrays, LDA cards, PCR, etc.) to advanced bioinformatics. CLC bio is one of several platforms used by Aros; others include technologies from Affymetrix, Illumina, Agilent, Qiagen, Fluidigm, and Applied Biosystems.

    Aros and CLC bio teamed up last year with Roche and Aarhus University Hospital's Institute of Pathology and the Research Unit for Molecular Medicine for the large-scale sequence analysis of formalin fixed, paraffin embedded (FFPE) tissue samples. Half of that project’s $5 million budget was funded by the Danish National Advanced Technology Foundation.

    "Having a very positive relationship with Aros Applied Biotechnology through our commitments in the FFPE project, it was a natural step for us to partner formally,” states Thomas Knudsen, CEO of CLC bio.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Ebola Vaccines

When do you think an Ebola vaccine will be available for the general public?